Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

42,576 stories, page 531 of 710

Advanced search

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Kailera’s oral obesity pill posts Phase 3 gains

Longevity.TechnologyOriginal source

🇺🇰Jul 13Regulatorygov.ukTier 1 · Regulatory source

The UK and the EU Drugs Agency sign a working arrangement

Government signs a working arrangement with the EU Drugs Agency to protect public health and reduce...

UK Department of Health and Social CareOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Defining Supply Chain Impact When Transitioning to Reusable Packaging

Pharmaceutical CommerceOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Edgewise Therapeutics Completes Up to $2.65 Billion Sevasemten Sale to Focus on Cardiovascular Pipeline

citybizOriginal source

🌍Jul 13Researchuab.eduTier 2 · Direct publisher

Cancer patient’s miraculous journey defying a diagnosis that could have killed him

University of Alabama at BirminghamOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Leqembi Autoinjector Matches IV Drip From Day One, AAIC 2026 Data Show

Tech TimesOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

All eyes on data on Biogen’s tau therapy

STATOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA accepts BioMarin application for full VOXZOGO approval By Investing.com

Investing.com IndiaOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

$12M pharmaceutical manufacturing facility to be built in Sugar Land

InnovationMapOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Oncolytics Biotech stock jumps on FDA meeting plans for trial

Investing.comOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $374.08, Implies 6% Upside

TradingViewOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA presents route to improve operational efficiency of drug manufacturing

European Pharmaceutical ReviewOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Isolator Market to reach USD 4.13 Billion by 2035 at 10.8% CAGR

EIN PresswireOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA starts full review of BioMarin’s VOXZOGO for children with achondroplasia

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

PR NewswireOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Biotech Rallies as Memory Chip Stocks Slide Premarket

TradingPediaOriginal source

🇺🇰Jul 13Regulatorygov.ukTier 1 · Regulatory source

Diphtheria: migrant health guide

Advice and guidance on the health needs of migrant patients for healthcare practitioners

UK Health Security AgencyOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Cosmo Bio USA Expands its Portfolio with ELISA Kits from Reed Biotech

EIN PresswireOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Vastpro Pharmaceutical discovers new voltage-gated sodium channel blockers

BioWorld NewsOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

The FDA keeps breaking its word to dying patients

Washington ExaminerOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Oncolytics Biotech® Reports FDA Regulatory Milestone and

GlobeNewswireOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Iodide Powders Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Demand and Feed Fortification

IndexBoxOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

TradingViewOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Cancer drug Multikine heads into 212-patient global trial for head and neck tumors

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Healthcare Monitor 2025-2026: Pharmaceutical companies must better respond to website quality, target-group-oriented communication, and AI visibility

Business WireOriginal source

🌍Jul 13Industrymatinasbiopharma.comTier 1 · Company source

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Matinas BioPharmaOriginal source

🇨🇦Jul 13Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Oribe Serene Scalp Densifying Shampoo; Presence of bacterial contamination

Affected lots may contain the presence of bacterial contamination (pluralibacter gergoviae).

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 13Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

BD ChloraPrep™ Clear - 1mL Applicator: Product sterility

Product sterility could be compromised in affected lots.

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 13Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Apo-Tiotropium Capsules; Out-of-specification (particle size)

The particle size did not meet the specifications in the affected lots.

Health Canada Recalls and Safety AlertsOriginal source

🇺🇸Jul 13CROir.criver.comTier 2 · Direct publisher

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

Charles River LaboratoriesOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

The Manila TimesOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA Cancels Food Licenses of Three Hotels in Nagpur

Nagpur TodayOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of Protect Pharmaceutical Corp – OTC:PRTT

TradingViewOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

BioSpaceOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

BioSpaceOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH

RTTNewsOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Ocugen Announces Binding Term Sheet for OCU400 License Deal in MENA Region with Roots Pharmaceutical

Quiver QuantitativeOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech AG Announces AI Collaboration with Ardigen to Support BiTAC Cancer Therapeutics Pipeline

Quiver QuantitativeOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Gene therapy for inherited blindness set for MENA launch under Ocugen–Roots pact

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

This Biotech Lets Rare-Disease Families Invest In Its Gene Therapy

ForbesOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

AI partnership aims to sharpen cancer target selection at VERAXA

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA backs pediatric study framework for Armata’s Staph infection therapy AP-SA02

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

Biotech startup funding gap widens despite rebound in VC investment

BioPharma DiveOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutra

GuruFocusOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

The Wrong Way To Compete With China in Biotech

RealClearDefenseOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical (TAK) holder to resell 51,579 ADSs under Rule 144

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

[8-K] AGENUS INC Reports Material Event

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awards

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical (NYSE: TAK) plans sale of 24,887 ADSs valued at $416,850

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

China’s Pharmaceutical Innovation: 30% of Global Drug Pipeline and Record Deals in 2026 - News and Statistics

IndexBoxOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical (TAK) files notice to sell 7,889 ADSs on NYSE

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Takeda Pharmaceutical (TAK) holder to sell 54,210 ADSs after RSU vesting

Stock TitanOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Tethis expands global access to SmartBioSurface through new channel partners

Scientist LiveOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Should You Invest in the VanEck Biotech ETF (BBH)?

Yahoo FinanceOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Direct-to-Patient Distribution Models Outpace Existing Safety Oversight Infrastructure

geneonline.comOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

[144] TAKEDA PHARMACEUTICAL CO LTD SEC Filing

Stock TitanOriginal source

🇺🇰Jul 13Regulatorygov.ukTier 1 · Regulatory source

Patient Safety Commissioner annual report 2025 to 2026

Patient Safety Commissioner annual report for the financial year 2025 to 2026.

UK Department of Health and Social CareOriginal source

🇺🇸Jul 13Regulatoryfda.govTier 1 · Regulatory source

CDER proposes to withdraw approval of TAVNEOS

FDA Drug Safety CommunicationsOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Goldman Sachs initiates Erasca stock coverage as early-stage biotech

Investing.comOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Business WireOriginal source